Management of Neutrophilia and Lymphopenia in Autoimmune Disorders

Initial Diagnostic Evaluation

A complete blood count with differential, peripheral blood smear, and reticulocyte count should be performed to confirm neutrophilia and lymphopenia and assess for other cell line abnormalities, as recommended by the American Society of Clinical Oncology 1, 2
A comprehensive history should be taken, focusing on current medications, especially immunosuppressive agents that can affect lymphocyte counts, recent infections or viral exposures, type and status of underlying autoimmune disease, and family history of autoimmunity, according to the American College of Rheumatology 1, 3, 4
Physical examination should include assessment of spleen size, signs of infection or inflammation, and evidence of autoimmune disease activity, as suggested by the European Society for Medical Oncology 1, 3, 5, 6

Viral studies, including CMV, HHV6, EBV, parvovirus, and HIV, should be conducted to identify potential underlying infections, as recommended by the Infectious Diseases Society of America 1, 3
Bacterial cultures and evaluation for infection (fungal, viral, bacterial) should be performed to rule out infectious complications, according to the American Society for Microbiology 1, 3
Nutritional assessments, including B12, folate, iron, copper, ceruloplasmin, and vitamin D, should be conducted to identify potential deficiencies, as suggested by the American Society of Hematology 1
Serum LDH and renal function tests should be performed to assess for potential organ damage, as recommended by the National Kidney Foundation 1
Autoimmune markers relevant to the patient's underlying condition should be evaluated to assess disease activity, according to the American College of Rheumatology 7

For Grade 1-2 lymphopenia (500-1,000 lymphocytes/μL), close monitoring with regular CBC checks is recommended, as suggested by the American Society of Clinical Oncology 3
For Grade 3 lymphopenia (250-499 lymphocytes/μL), weekly CBC monitoring and consideration of CMV screening are recommended, according to the Centers for Disease Control and Prevention 3, 4
For Grade 4 lymphopenia (<250 lymphocytes/μL), initiation of Pneumocystis jirovecii prophylaxis, consideration of Mycobacterium avium complex prophylaxis, and implementation of CMV screening are recommended, as suggested by the Infectious Diseases Society of America 3, 4

If neutrophilia is associated with autoimmune disease flare, treatment of the underlying autoimmune condition according to disease-specific guidelines is recommended, as suggested by the American College of Rheumatology 7
If neutrophilia is medication-induced, consideration of medication adjustment and monitoring for infection risk are recommended, according to the American Society of Clinical Oncology 5, 6, 8

Patients with autoimmune disorders may have complex immune dysregulation, and lymphopenia may reflect increased apoptosis of lymphocytes, redistribution of lymphocytes to inflamed tissues, or effect of immunosuppressive medications, as suggested by the American College of Rheumatology 5, 6
Autoimmune cytopenias not responding to conventional autoimmune-oriented therapy may require more aggressive treatment of the underlying autoimmune condition, according to the European Society for Medical Oncology 7

For mild abnormalities without symptoms, close monitoring may be sufficient, as recommended by the American Society of Clinical Oncology 3, 2
For moderate to severe abnormalities or symptomatic patients, corticosteroids are the first-line treatment for many autoimmune-related cytopenias, according to the American College of Rheumatology 7

Regular CBC monitoring (frequency based on severity of abnormalities) is recommended, as suggested by the American Society of Clinical Oncology 1, 3
Vigilance for signs of infection, especially with severe lymphopenia, is essential, according to the Infectious Diseases Society of America 3, 4
Assessment of response to treatment and adjustment as needed are crucial, as recommended by the American College of Rheumatology 7

Distinguishing between disease flare, medication effect, and new-onset infection can be challenging, as suggested by the American Society of Clinical Oncology 5, 6
Lymphopenia increases risk for opportunistic infections; prophylaxis should be considered for severe cases, according to the Infectious Diseases Society of America 3, 4